Enliven Therapeutics Inc
XNAS:ELVN 4:00:00 PM EDT
| Market Cap (Intraday) | 1.01B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $17.81 |
| 50-Day MA | $20.37 |
| 200-Day MA | $19.89 |
Enliven Therapeutics Inc Stock, XNAS:ELVN
6200 Lookout Road, Suite 300, Boulder, Colorado 80301
United States of America
Phone: +1.720.647.8519
Number of Employees: 62
Description
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.